Top

Published in:

Open Access 01-12-2010 | Research

New-generation taxoid SB-T-1214 inhibits stem cell-related gene expression in 3D cancer spheroids induced by purified colon tumor-initiating cells

Authors: Galina I Botchkina, Edison S Zuniga, Manisha Das, Yuan Wang, Haichao Wang, Shu Zhu, Anne G Savitt, Rebecca A Rowehl, Yan Leyfman, Jingfang Ju, Kenneth Shroyer, Iwao Ojima

Published in: Molecular Cancer | Issue 1/2010

Abstract

Background

Growing evidence suggests that the majority of tumors are organized hierarchically, comprising a population of tumor-initiating, or cancer stem cells (CSCs) responsible for tumor development, maintenance and resistance to drugs. Previously we have shown that the CD133^high/CD44^high fraction of colon cancer cells is different from their bulk counterparts at the functional, morphological and genomic levels. In contrast to the majority of colon cancer cells expressing moderate levels of CD133, CD44 and CD166, cells with a high combined expression of CD133 and CD44 possessed several characteristic stem cell features, including profound self-renewal capacity in vivo and in vitro, and the ability to give rise to different cell phenotypes. The present study was undertaken for two aims: a) to determine stem cell-related genomic characteristics of floating 3D multicellular spheroids induced by CD133^high/CD44^high colon cancer cells; and b) to evaluate CSC-specific alterations induced by new-generation taxoid SB-T-1214.

Results

Selected CSC phenotype was isolated from three independent invasive colon cancer cell lines, HCT116, HT29 and DLD-1. A stem cell-specific PCR array assay (SA Biosciences) revealed that colonospheres induced by purified CD133^high/CD44^high expressing cells display profound up-regulation of stem cell-related genes in comparison with their bulk counterparts. The FACS analysis has shown that the 3D colonospheres contained some minority cell populations with high levels of expression of Oct4, Sox2, Nanog and c-Myc, which are essential for stem cell pluripotency and self-renewal. Single administration of the SB-T-1214 at concentration 100 nM-1 μM for 48 hr not only induced growth inhibition and apoptotic cell death in these three types of colon cancer spheroids in 3D culture, but also mediated massive inhibition of the stem cell-related genes and significant down-regulation of the pluripotency gene expression. PCR array and FACS data were confirmed with western blotting. Importantly, viable cells that survived this treatment regimen were no longer able to induce secondary floating spheroids and exhibited significant morphological abnormalities.

Conclusions

We report here that a new-generation taxoid SB-T-1214 possesses significant activity against colon cancer spheroids induced by and enriched with drug resistant tumorigenic CD133^high/CD44^high cells and efficiently inhibited expression of the majority of stem cell-related genes. Our data indicates that the previously observed long-term efficacy of SB-T-1214 against drug resistant colon tumors in vivo may be explained by the down-regulation of multiple stem cell-related genes in the tumorigenic cell population, in addition to its known efficacy as a mitotic poison against proliferating cancer cells.

Available only for authorised users

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics. CA Cancer J Clin. 2009, 59: 225-249. 10.3322/caac.20006CrossRefPubMed

Kamb A, Wee S, Lengauer C: Why is cancer drug discovery so difficult?. Nature Rev Drug Discovery. 2007, 6: 115-120. 10.1038/nrd2155.CrossRef

Dalerba P, Cho RW, Clarke MF: Cancer Stem Cells: Models and Concepts. Annual Rev Med. 2007, 58: 267-284. 10.1146/annurev.med.58.062105.204854.CrossRef

Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB: Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003, 63: 5821-5828.PubMed

Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR, Lu L, Irvin D, Black KL, Yu JS: Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer. 2006, 5: 67- 10.1186/1476-4598-5-67PubMedCentralCrossRefPubMed

Bussolati B, Bruno S, Grange C, Buttiglieri S, Deregibus MC, Cantino D, Camussi G: Isolation of renal progenitor cells from adult human kidney. Am J Pathol. 2005, 166: 545-555.PubMedCentralCrossRefPubMed

Suetsugu A, Nagaki M, Aoki H, Motohashi T, Kunisada T, Moriwaki H: Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem and Biophys Res Comm. 2006, 351: 820-824. 10.1016/j.bbrc.2006.10.128.CrossRef

Yin S, Li J, Hu C, Chen X, Yao M: CD133 positive hepatocellular carcinoma cells posess high capacity for tumorigenicity. Int J Cancer. 2007, 120: 1444-1450. 10.1002/ijc.22476CrossRefPubMed

O'Brien CA, Pollett A, Gallinger S, Dick J: A human colon cancer cell capable of initiating timor growth in immunodeficient mice. Nature. 2007, 445: 106-110. 10.1038/nature05372CrossRefPubMed

10.

Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, De Maria R: Identification and expansion of human colon-cancer-initiating cells. Nature. 2007, 445: 111-115. 10.1038/nature05384CrossRefPubMed

11.

Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, Bruns CJ, Heeschen C: Distinct Populations of Cancer Stem Cells Determine Tumor Growth and Metastatic Activity in Human Pancreatic Cancer. Cell Stem Cell. 2007, 1: 313-323. 10.1016/j.stem.2007.06.002CrossRefPubMed

12.

Shmelkov SV, Clair R, Lyden D, Rafii S: AC133/CD133/Prominin-1. Int J Biochem Cell Biol. 2005, 37: 715-719. 10.1016/j.biocel.2004.08.010CrossRefPubMed

13.

Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ: Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005, 65: 10946-51. 10.1158/0008-5472.CAN-05-2018CrossRefPubMed

14.

Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE: Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med. 2006, 10: 1167-74. 10.1038/nm1483.CrossRef

15.

Krause DS, Lazarides K, von Andrian UH, Van Etten RA: Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells. Nat Med. 2006, 10: 1175-80. 10.1038/nm1489.CrossRef

16.

Patrawala L, Calhoun T, Schneider-Broussard R, Li H, Bhatia B, Tang S, Reilly JG, Chandra D, Zhou J, Claypool K, Coghlan L, Tang DG: Highly purified CD44⁺ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene. 2006, 25: 1696-1708. 10.1038/sj.onc.1209327CrossRefPubMed

17.

Dalerba P, Dylla SJ, Park IK, Liu R, Wang X, Cho RW, Hoey T, Gurney A, Huang EH, Simeone DM, Shelton AA, Parmiani G, Castelli C, Clarke MF: Phenotypic characterization of human colorectal cancer stem cells. PNAS USA. 2007, 104: 10158-63. 10.1073/pnas.0703478104PubMedCentralCrossRefPubMed

18.

Haraguch M, Ohkuma M, Sakashita H, Matsuzaki S, Tanaka F, Mimori K, Kamohara Y, Inoue H, Mori M: CD133⁺CD44⁺ Population Efficiently Enriches Colon Cancer Initiating Cells. Ann Surgical Oncol. 2008, 15: 2927-2933. 10.1245/s10434-008-0074-0.CrossRef

19.

Rowehl RH, Crawford H, Dufour A, Leyfman Y, Ju J, Botchkina GI: Genomic Analysis of Prostate Cancer Stem Cells Isolated from Highly Metastatic Cell Line. Cancer Genomics and Proteomics. 2008, 5: 301-309.PubMed

20.

Botchkina IL, Rowehl RA, Rivadeneira DE, Karpeh MS, Crawford H, Dufour A, Ju J, Weng Y, Leyfman Y, Botchkina GI: Phenotypic Subpopulations of Metastatic Colon Cancer Stem Cells: Genomic Analysis. Cancer Genomics and Proteomics. 2009, 6: 19-30.PubMed

21.

Hong SP, Wen J, Bang S, Park S, Song SY: CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells. Internatiionl J Cancer. 2009, 125 (10): 2323-31. 10.1002/ijc.24573.CrossRef

22.

Takaishi , Shigeo , Okumura , Tomoyuki , Tu , Shuiping , Wang , Sophie SW, Shibata , Wataru , Vigneshwaran , Ramanathan , Gordon , Shanisha AK, Shimada , Yutaka , Wang , Timothy C: Identification of Gastric Cancer Stem Cells Using the Cell Surface Marker CD44. Stem Cells. 2009, 27: 1006-1020. 10.1002/stem.30PubMedCentralCrossRefPubMed

23.

Ponta H, Sherman L, Herrlich PA: CD44: From adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol. 2003, 4 (1): 33-45. 10.1038/nrm1004CrossRefPubMed

24.

Marhaba R, Zöller M: CD44 in cancer progression: adhesion, migration and growth regulation. J Mol Histol. 2004, 35 (3): 211-31. 10.1023/B:HIJO.0000032354.94213.69CrossRefPubMed

25.

Gotley DC, Fawcett J, Walsh MD, Reeder JA, Simmons DL, Antalis TM: Alternatively spliced variants of the cell adhesion molecule CD44 and tumour progression in colorectal cancer. Br J Cancer. Br J Cancer. 1996, 74 (3): 342-51.PubMedCentralCrossRefPubMed

26.

Frank NY, Pendse SS, Lapchak PH, Margaryan A, Shlain D, Doeing C, Sayegh MH, Frank MH: Regulation of progenitor cell fusion by ABCB5 P-glycoprotein, a novel human ATP-binding cassette transporter. J Biol Chem. 2003, 278: 47156-47165. 10.1074/jbc.M308700200CrossRefPubMed

27.

Frank NY, Margaryan A, Huang Y, Schatton T, Waaga-Gasser AM, Gasser M, Sayegh MH, Sadee W, Frank MH: ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res. 2005, 65: 4320-4333. 10.1158/0008-5472.CAN-04-3327CrossRefPubMed

28.

Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmelad AB, Dewhirst MW, Bigner DD, Rich JN: Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006, 444: 756-760. 10.1038/nature05236CrossRefPubMed

29.

30.

Bertolini G, Roz L, Perego P, Tortoreto M, Fontanella E, Gatti L, Pratesi G, Fabbri A, Andriani F, Tinelli S, Roz E, Caserini R, Lo Vullo S, Camerini T, Mariani L, Delia D, Calabrò E, Pastorino U, Sozzi G: Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. PNAS. 2009, 106: 16281-16286. 10.1073/pnas.0905653106PubMedCentralCrossRefPubMed

31.

Dallas NA, Xia L, Fan F, Gray MJ, Gaur P, van Buren G, Samuel S, Kim MP, Lim SJ, Ellis LM: Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Res. 2009, 69 (5): 1951-7. 10.1158/0008-5472.CAN-08-2023PubMedCentralCrossRefPubMed

32.

Vlashi E, McBride WH, Pajonk F: Radiation responses of cancer stem cells. J Cell Biochem. 2009, 108 (2): 339-42. 10.1002/jcb.22275PubMedCentralCrossRefPubMed

33.

Liu Q, Nguyen DH, Dong Q, Shitaku P, Chung K, Liu OY, Tso JL, Liu JY, Konkankit V, Cloughesy TF, Mischel PS, Lane TF, Liau LM, Nelson SF, Tso CL: Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors. J Neurooncol. 2009, 94 (1): 1-19. 10.1007/s11060-009-9919-zPubMedCentralCrossRefPubMed

34.

Dirks PB: Cancer: Stem cells and brain tumours. Nature. 2006, 444: 687-688. 10.1038/444687aCrossRefPubMed

35.

Eramo A, Ricci-Vitiani L, Zeuner A, Pallini R, Lotti F, Sette G, Pilozzi E, Larocca LM, Peschle C, De Maria R: Chemotherapy resistance of glioblastoma stem cells. Cell Death and Differentiation. 2006, 13: 1238-1241. 10.1038/sj.cdd.4401872CrossRefPubMed

36.

Woodward WA, Chen MS, Behbod F, Alfaro MP, Buchholz TA, Rosen JM: WNT/β-catenin mediates radiation resistance of mouse mammary progenitor cells. PNAS USA. 2007, 104: 618-623. 10.1073/pnas.0606599104PubMedCentralCrossRefPubMed

37.

Todaro M, Alea MP, Stefano AB, Cammareri P, Vermeulen L, Iovino F, Tripodo C, Russo A, Gulotta G, Medema JP, Stassi G: Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell. 2007, 1: 389-402. 10.1016/j.stem.2007.08.001CrossRefPubMed

38.

Bleau AM, Hambardzumyan D, Ozawa T, Fomchenko EI, Huse JT, Brennan CW, Holland EC: PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell. 2009, 4 (3): 226-35. 10.1016/j.stem.2009.01.007PubMedCentralCrossRefPubMed

39.

Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF: Prospective identification of tumorigenic breast cancer cells. PNAS USA. 2003, 100: 3983-3988. 10.1073/pnas.0530291100PubMedCentralCrossRefPubMed

40.

Zeppernick F, Ahmadi R, Campos B, Dictus C, Helmke BM, Becker N, Lichter P, Unterberg A, Radlwimmer B, Herold-Mende CC: Stem Cell Marker CD133 Affects Clinical Outcome in Glioma Patients. Clin Cancer Res. 2008, 14: 123-129. 10.1158/1078-0432.CCR-07-0932CrossRefPubMed

41.

Maeda S, Shinchi HH, Kurahara HY, Mataki Y, Maemura K, Sato M, Natsugoe S, Aikou T, Takao SS: CD133 expression is correlated with lymph node metastasis and vascular endothelial growth factor-C expression in pancreatic cancer. British J Cancer. 2008, 98: 1389-1397. 10.1038/sj.bjc.6604307.CrossRef

42.

Horst D, Kriegl L, Engel J, Kirchner T, Jung A: CD133 expression is an independent prognostic marker for low survival in colorectal cancer. Br J Cancer. 2008, 99 (8): 1285-9. 10.1038/sj.bjc.6604664PubMedCentralCrossRefPubMed

43.

Dean M, Fojo T, Bates S: Tumor stem cell and drug resistance. Nat Rev Cancer. 2005, 5: 275-284. 10.1038/nrc1590CrossRefPubMed

44.

Donnenberg VS, Donnenberg AD: Multiple drug resistance in cancer revisited: the cancer stem cell hypothesis. J Clin Pharmacol. 2005, 45: 872-877. 10.1177/0091270005276905CrossRefPubMed

45.

Mimeault M, Hauke R, Mehra PP, Batra SK: Recent advances in cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers. J Cell Mol Med. 2007, 11: 981-1011. 10.1111/j.1582-4934.2007.00088.xPubMedCentralCrossRefPubMed

46.

Ojima I, Chen J, Sun L, Borella CP, Wang T, Miller ML, Lin S, Geng X, Kuznetsova L, Qu C, Gallager D, Zhao X, Zanardi I, Xia S, Horwitz SB, Mallen-St Clair J, Guerriero JL, Bar-Sagi D, Veith JM, Pera P, Bernacki RJ: Design, Synthesis and Biological Evaluation of New Generation Taxoids. J Med Chem. 2008, 51: 3203-3221. 10.1021/jm800086ePubMedCentralCrossRefPubMed

47.

Ehrlichová M, Václavíková R, Ojima I, Pepe A, Kuznetsova LV, Chen J, Truksa J, Ková J, Gut I: Transport and cytotoxicity of paclitaxel, docetaxel, and novel taxanes in human breast cancer cells. N-S Arch Pharmacol. 2005, 372: 95-105. 10.1007/s00210-005-1080-4.CrossRef

48.

Kovar J, Ehrlichova M, Smejkalova B, Zanardi I, Ojima I, Gut I: Comparison of cell death-inducing effect of novel taxane SB-T-1216 and paclitaxel in breast cancer cells. Anticancer Res. 2009, 29 (8): 2951-2960.PubMedCentralPubMed

49.

Kuznetsova L, Chen JL, Sun X, Wu A, Pepe JM, Veith P, Pera RJ, Bernacki , Ojima I: Syntheses and Evaluation of Novel Fatty Acid-2nd-generation Taxoid Conjugates as Promising Anticancer Agents. Bioorg Med Chem Let. 2006, 16: 974-977. 10.1016/j.bmcl.2005.10.089.CrossRef

50.

Takahashi K, Yamanaka S: Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006, 126: 663-676. 10.1016/j.cell.2006.07.024CrossRefPubMed

51.

Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S: Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007, 131: 861-872. 10.1016/j.cell.2007.11.019CrossRefPubMed

52.

Kirkland SC: Type I collagen inhibits differentiation and promotes a stem cell-like phenotype in human colorectal carcinoma cells. Br J Cancer. 2009, 101 (2): 320-326. 10.1038/sj.bjc.6605143PubMedCentralCrossRefPubMed

53.

Said HM, Polat B, Hagemann C, Anacker J, Flentje M, Vordermark D: Absence of GAPDH regulation in tumor-cells of different origin under hypoxic conditions in - vitro. BMC Res Notes. 2009, 2: 8- 10.1186/1756-0500-2-8PubMedCentralCrossRefPubMed

54.

Wagers AJ, Weissman IL: Plasticity of adult stem cells. Cell. 2004, 116: 639-648. 10.1016/S0092-8674(04)00208-9CrossRefPubMed

55.

Jensen JB, Parmar M: Strengths and limitations of the neurosphere culture system. Mol Neurobiol. 2006, 34: 153-161. 10.1385/MN:34:3:153CrossRefPubMed

56.

Shmelkov SV, Butler JM, Hooper AT, Hormigo A, Kushner J, Milde T, St Clair R, Baljevic M, White I, Jin DK, Chadburn A, Murphy AJ, Valenzuela DM, Gale NW, Thurston G, Yancopoulos GD, D'Angelica M, Kemeny N, Lyden D, Rafii S: CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. J Clinical Investigation. 2008, 118: 2111-2120.

57.

Zhu L, Gibson P, Currle DS, Tong Y, Richardson RJ, Bayazitov IT, Poppleton H, Zakharenko S, Ellison DW, Gilbertson RJ: Prominin 1 marks intestinal stem cells that are susceptible to neoplastic transformation. Nature. 2009, 457 (7229): 603-607. 10.1038/nature07589PubMedCentralCrossRefPubMed

58.

Puglisi MA, Sgambato A, Saulnier N, Rafanelli F, Barba M, Boninsegna A, Piscaglia AC, Lauritano C, Novi ML, Barbaro F, Rinninella E, Campanale C, Giuliante F, Nuzzo G, Alfieri S, Doglietto GB, Cittadini A, Gasbarrini A: Isolation and characterization of CD133+ cell population within human primary and metastatic colon cancer. Eur Rev Med Pharmacol Sci. 2009, 55-62. Suppl 1,

59.

Du L, Wang H, He L, Zhang J, Ni B, Wang X, Jin H, Cahuzac N, Mehrpour M, Lu Y, Chen Q: CD44 is of Functional Importance for Colorectal Cancer Stem Cells. Clin Cancer Res. 2008, 14: 6751-6760. 10.1158/1078-0432.CCR-08-1034CrossRefPubMed

60.

Horst D, Kriegl L, Engel J, Kirchner T, Jung A: Prognostic Significance of the Cancer Stem Cell Markers CD133, CD44, and CD166 in Colorectal Cancer. Cancer Investigation. 2009, 27: 844-850. 10.1080/07357900902744502CrossRefPubMed

61.

Zhu Z, Hao X, Yan M, Yao M, Ge C, Gu J, Li J: Cancer stem/progenitor cells are highly enriched in CD133(+)CD44(+) population in hepatocellular carcinoma. Int J Cancer. 2009,

62.

Mueller-Klieser W: Three-dimensional cell cultures: from molecular mechanisms to clinical applications. Am J Physiol. 1997, 273: C1109-C1123.PubMed

63.

Santini MT, Rainaldi G: Three-dimensional spheroid model in tumor biology. Pathobiology. 1999, 67: 148-157. 10.1159/000028065CrossRefPubMed

64.

Dubessy C, Merlin JM, Marchal C, Guillemin F: Spheroids in radiobiology and photodynamic therapy. Crit Rev Oncol Hematol. 2000, 36: 179-192. 10.1016/S1040-8428(00)00085-8CrossRefPubMed

65.

Durand RE, Olive PL: Resistance of tumor cells to chemo- and radiotherapy modulated by the three-dimensional architecture of solid tumors and spheroids. Methods Cell Biol. 2001, 64: 211-233. 2001, full_textCrossRefPubMed

66.

Inch WR, McCredie JA, Sutherland RM: Growth of nodular carcinomas in rodents compared with multi-cell spheroids in tissue culture. Growth. 1970, 34: 271-282.PubMed

67.

Sutherland RM, McCredie JA, Inch WR: Growth of multicellular spheroids in tissue culture as a model of nodular carcinomas. J Nat Cancer Inst. 1971, 46: 113-120.PubMed

68.

Hamilton G: Multicellular spheroids as an in vitro tumor model. Cancer Lett. 1998, 131: 29-34. 10.1016/S0304-3835(98)00198-0CrossRefPubMed

69.

Csete M: Oxygen in the cultivation of stem cells. Stem cell biology: Development and plasticity, Ann NY Acad. 2005, 1049: 1-8.

70.

Friedrich J, Siedel C, Ebner R, Kunz-Schughart LA: Spheroid-based drug screening: considerations and practical approach. Nature Protocols. 2009, 4: 309-324. 10.1038/nprot.2008.226CrossRefPubMed

71.

Sodek KL, Ringuette MJ, Brown TJ: Compact spheroid formation by ovarian cancer cells is associated with contractile behavior and an invasive phenotype. Int J Cancer. 2009, 124 (9): 2060-2070. 10.1002/ijc.24188CrossRefPubMed

72.

Todaro M, D'Asaro M, Caccamo N, Iovino F, Francipane MG, Meraviglia S, Orlando V, La Mendola C, Gulotta G, Salerno A, Dieli F, Stassi G: Efficient killing of human colon cancer stem cells by gammadelta T lymphocytes. J Immunol. 2009, 182 (11): 7287-96. 10.4049/jimmunol.0804288CrossRefPubMed

73.

Grimshaw MJ, Cooper L, Papazisis K, Coleman JA, Bohnenkamp HR, Chiapero-Stanke L, Taylor-Papadimitriou J, Burchell JM: Mammosphere culture of metastatic breast cancer cells enriches for tumorigenic breast cancer cells. Breast Cancer Res. 2008, 10 (3): R52- 10.1186/bcr2106PubMedCentralCrossRefPubMed

74.

Kobayashi H, Man S, Graham CH, Kapitain SJ, Teicher BA, Kerbel RS: Acquired multicellular-mediated resistance to alkylating agents in cancer. PNAS USA. 1993, 90: 3294-3298. 10.1073/pnas.90.8.3294PubMedCentralCrossRefPubMed

75.

Mueller-Klieser W: Tumor biology and experimental therapeutics. Crit Rev Oncol Hematol. 2000, 36: 123-139. 10.1016/S1040-8428(00)00082-2CrossRefPubMed

76.

Gaedtke L, Thoenes L, Culmsee C, Mayer B, Wagner E: Proteomic Analysis Reveals Differences in Protein Expression in Spheroid versus Monolayer Cultures of Low-Passage Colon Carcinoma Cells. J Proteome Res. 2007, 6 (11): 4111-4118. 10.1021/pr0700596CrossRefPubMed

77.

Barbone D, Yang TM, Morgan JR, Gaudino G, Broaddus VC: Mammalian target of rapamycin contributes to the acquired apoptotic resistance of human mesothelioma multicellular spheroids. J Biol Chem. 2008, 283: 13021-13030. 10.1074/jbc.M709698200PubMedCentralCrossRefPubMed

78.

Desoize B, Jardillier J: Multicellular resistance: a paradigm for clinical resistance?. Crit Rev Oncol Hematol. 2000, 36: 193-207. 10.1016/S1040-8428(00)00086-XCrossRefPubMed

79.

Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget JJL, Tian S, Nie J, Jonsdottir GA, Ruotti V, Stewart R, Slukvin II, Thomson JA: Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells. Science. 2007, 318: 1917-1920. 10.1126/science.1151526CrossRefPubMed

80.

Chen YC, Hsu HS, Chen YW, Tsai TH, How CK, Wang CY, Hung SC, Chang YL, Tsai ML, Lee YY, Ku HH, Chiou SH: Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells. PLoS One. 2008, 3 (7): e2637- 10.1371/journal.pone.0002637PubMedCentralCrossRefPubMed

81.

Wang Q, He W, Lu C, Wang Z, Wang J, Giercksky KE, Nesland JM, Suo Z: Oct3/4 and Sox2 are significantly associated with an unfavorable clinical outcome in human esophageal squamous cell carcinoma. Anticancer Res. 2009, 29 (4): 1233-41.PubMed

82.

Park IH, Zhao R, West JA, Yabuuchi A, Huo H, Ince TA, Lerou PH, Lensch MW, Daley GQ: Reprogramming of human somatic cells to pluripotency with defined factors. Nature. 2008, 451 (7175): 141-6. 10.1038/nature06534CrossRefPubMed

83.

Ojima I, Das M: Recent Advances in the Chemistry and Biology of New Generation Taxoids. J Nat Prod. 2009, 72 (3): 554-65. 10.1021/np8006556PubMedCentralCrossRefPubMed

84.

Jordan MA, Wilson L: Microtubules as a target for anticancer drugs. Nat Rev Cancer. 2004, 4 (4): 253-65. 10.1038/nrc1317CrossRefPubMed

Title: New-generation taxoid SB-T-1214 inhibits stem cell-related gene expression in 3D cancer spheroids induced by purified colon tumor-initiating cells
Authors: Galina I Botchkina
Edison S Zuniga
Manisha Das
Yuan Wang
Haichao Wang
Shu Zhu
Anne G Savitt
Rebecca A Rowehl
Yan Leyfman
Jingfang Ju
Kenneth Shroyer
Iwao Ojima
Publication date: 01-12-2010
Publisher: BioMed Central
Published in: Molecular Cancer / Issue 1/2010
Electronic ISSN: 1476-4598
DOI: https://doi.org/10.1186/1476-4598-9-192

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2010

Breast carcinoma cells re-express E-cadherin during mesenchymal to epithelial reverting transition

Synergistic epigenetic reactivation of estrogen receptor-α (ERα) by combined green tea polyphenol and histone deacetylase inhibitor in ERα-negative breast cancer cells

t-DARPP regulates phosphatidylinositol-3-kinase-dependent cell growth in breast cancer

Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP)-targeted delivery of soluble TRAIL potently inhibits melanoma outgrowth in vitro and in vivo

Dissecting the roles of DR4, DR5 and c-FLIP in the regulation of Geranylgeranyltransferase I inhibition-mediated augmentation of TRAIL-induced apoptosis

Microprocessor of microRNAs: regulation and potential for therapeutic intervention

Keynote webinar | Spotlight on antibody–drug conjugates in cancer